Vor Biopharma Inc (VOR) - Total Liabilities
Based on the latest financial reports, Vor Biopharma Inc (VOR) has total liabilities worth $681.25 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Vor Biopharma Inc to evaluate the company's liquid asset resilience ratio.
Vor Biopharma Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Vor Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Vor Biopharma Inc asset portfolio.
Vor Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Vor Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alphamin Res
V:AFM
|
Canada | CA$149.18 Million |
|
Cpi Fim SA
WAR:OPG
|
Poland | zł4.75 Billion |
|
Aptus Value Housing Finance India Limited
NSE:APTUS
|
India | Rs79.88 Billion |
|
China Yuchai International Limited
NYSE:CYD
|
USA | $14.75 Billion |
|
Suzhou Victory Precision Manufacture Co Ltd
SHE:002426
|
China | CN¥4.18 Billion |
|
Stanley Fertilizer Co Ltd
SHE:002588
|
China | CN¥6.79 Billion |
|
Taiwan FamilyMart Co Ltd
TWO:5903
|
Taiwan | NT$70.88 Billion |
|
Max Stock Ltd
TA:MAXO
|
Israel | ILA1.10 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Vor Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Vor Biopharma Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vor Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vor Biopharma Inc (2018–2025)
The table below shows the annual total liabilities of Vor Biopharma Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $628.44 Million | +1259.46% |
| 2024-12-31 | $46.23 Million | -21.79% |
| 2023-12-31 | $59.10 Million | +21.22% |
| 2022-12-31 | $48.76 Million | +85.21% |
| 2021-12-31 | $26.33 Million | -4.74% |
| 2020-12-31 | $27.64 Million | +1164.27% |
| 2019-12-31 | $2.19 Million | -71.88% |
| 2018-12-31 | $7.77 Million | -- |
About Vor Biopharma Inc
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with Re… Read more